ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma†,‡

被引:36
|
作者
Rodolakis, Alexandros [1 ]
Scambia, Giovanni [2 ]
Planchamp, Francois [3 ]
Acien, Maribel [4 ]
Sardo, Attilio Di Spiezio [5 ]
Farrugia, Martin [6 ]
Grynberg, Michael [7 ,8 ,9 ]
Pakiz, Maja [10 ]
Pavlakis, Kitty [11 ,12 ]
Vermeulen, Nathalie [13 ]
Zannoni, Gianfranco [14 ]
Zapardiel, Ignacio [15 ]
Macklon, Kirsten Louise Tryde [16 ]
机构
[1] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Unit Gynaecol Oncol, Sch Hlth Sci, Athens 11528, Greece
[2] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[3] Inst Bergonie, Clin Res Unit, Bordeaux, France
[4] Miguel Hernandez Univ, San Juan Univ Hosp, Obstet & Gynecol Dept, Alicante, Spain
[5] Univ Naples Federico II, Sch Med, Dept Publ Hlth, Gynecol & Obstet Unit, Naples, Campania, Italy
[6] Spencer Private Hosp, East Kent, England
[7] Hop Antoine Beclere, AP HP, Dept Reprod Med & Fertil Preservat, Clamart, France
[8] Hop Jean Verdier, AP HP, Dept Reprod Med & Fertil Preservat, Bondy, France
[9] Univ Paris Saclay, St Aubin, France
[10] Univ Med Ctr, Dept Gynecol & Breast Oncol, Maribor, Slovenia
[11] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Pathol Dept 1, Sch Hlth Sci, Athens, Slovenia
[12] IASO Womens Hosp, Pathol Dept, Athens, Greece
[13] European Soc Human Reprod & Embryol, Strombeek Bever, Belgium
[14] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Pathol, Dipartimento Sci Salute Donna & Bambino & Sanita, Rome, Italy
[15] La Paz Univ Hosp, Dept Gynecol Oncol, Madrid, Spain
[16] Copenhagen Univ Hosp, Fertil Dept, Copenhagen, Denmark
关键词
uterine cancer; guideline; fertility preservation; endometrial carcinoma; oncofertility; DEEP MYOMETRIAL INVASION; COMPLEX ATYPICAL HYPERPLASIA; DETECTING CERVICAL INVASION; POLYCYSTIC-OVARY-SYNDROME; YOUNG-WOMEN; TRANSVAGINAL ULTRASOUND; DIAGNOSTIC-ACCURACY; ESGO/ESTRO/ESP GUIDELINES; PREOPERATIVE ASSESSMENT; REPRODUCTIVE OUTCOMES;
D O I
10.1093/hropen/hoac057
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
STUDY QUESTION How should fertility-sparing treatment of patients with endometrial carcinoma be performed? SUMMARY ANSWER Forty-eight recommendations were formulated on fertility-sparing treatment of patients with endometrial carcinoma. WHAT IS KNOWN ALREADY The standard surgical treatment of endometrial carcinoma consisting of total hysterectomy with bilateral salpingo-oophorectomy drastically affects the quality of life of patients and creates a challenge for clinicians. Recent evidence-based guidelines of the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) provide comprehensive guidelines on all relevant issues of diagnosis and treatment in endometrial carcinoma in a multidisciplinary setting. While addressing also work-up for fertility preservation treatments and the management and follow-up for fertility preservation, it was considered relevant to further extend the guidance on fertility-sparing treatment. STUDY DESIGN, SIZE, DURATION A collaboration was set up between the ESGO, the European Society of Human Reproduction and Embryology (ESHRE) and the European Society for Gynaecological Endoscopy (ESGE), aiming to develop clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing treatment in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. PARTICIPANTS/MATERIALS, SETTING, METHODS ESGO/ESHRE/ESGE nominated an international multidisciplinary development group consisting of practising clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (11 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2016, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgement was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 95 independent international practitioners in cancer care delivery and patient representatives. MAIN RESULTS AND THE ROLE OF CHANCE The multidisciplinary development group formulated 48 recommendations in four sections; patient selection, tumour clinicopathological characteristics, treatment and special issues. LIMITATIONS, REASONS FOR CAUTION Of the 48 recommendations, none could be based on level I evidence and only 16 could be based on level II evidence, implicating that 66% of the recommendations are supported only by observational data, professional experience and consensus of the development group. WIDER IMPLICATIONS OF THE FINDINGS These recommendations provide guidance to professionals caring for women with endometrial carcinoma, including but not limited to professionals in the field of gynaecological oncology, onco-fertility, reproductive surgery, endoscopy, conservative surgery and histopathology, and will help towards a holistic and multidisciplinary approach for this challenging clinical scenario. STUDY FUNDING/COMPETING INTEREST(S) All costs relating to the development process were covered from ESGO, ESHRE and ESGE funds. There was no external funding of the development process or manuscript production. G.S. has reported grants from MSD Italia S.r.l., advisory boards for Storz, Bayer, Astrazeneca, Metronic, TESARO Bio Italy S.r. l and Johnson & Johnson, and honoraria for lectures from Clovis Oncology Italy S.r.l. M.G. has reported advisory boards for Gedeon Richter and Merck. The other authors have reported no conflicts of interest. DISCLAIMER This document represents the views of ESHRE, ESGO and ESGE which are the result of consensus between the relevant stakeholders and where relevant based on the scientific evidence available at the time of preparation. The recommendations should be used for informational and educational purposes. They should not be interpreted as setting a standard of care, or be deemed inclusive of all proper methods of care nor exclusive of other methods of care reasonably directed to obtaining the same results. They do not replace the need for application of clinical judgement to each individual presentation, nor variations based on locality and facility type.
引用
收藏
页数:20
相关论文
共 50 条
  • [41] Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia
    Zhang, Xiaobo
    Zhao, Xiaoya
    Wang, Chen
    Lu, Shanshan
    Wang, Yiqin
    He, Yijiao
    Wang, Jianliu
    Shen, Danhua
    ONCOLOGY LETTERS, 2023, 25 (02)
  • [42] Fertility-Sparing Approaches in Gynecologic Cancers: A Review of ESGO Task Force Activities
    Denschlag, Dominik
    Reed, Nicholas S.
    Rodolakis, Alex
    CURRENT ONCOLOGY REPORTS, 2012, 14 (06) : 535 - 538
  • [43] Fertility-sparing in cancer patients
    Karakas, Sema
    Kaya, Cihan
    Schafer, Sebastian Daniel
    Mikus, Mislav
    Terzic, Milan
    Abdullaev, Bekhzod
    Andrisani, Alessandra
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2021, 48 (04): : 787 - 794
  • [44] Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
    Ding, Yingqiao
    Fan, Yuan
    Li, Xingchen
    Wang, Yiqin
    Wang, Jianliu
    Tian, Li
    REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2022, 20 (01)
  • [45] Outcome of fertility-sparing treatment with medroxyprogesterone acetate for atypical hyperplasia and endometrial carcinoma in young Japanese women
    Kataoka, H.
    Mori, T.
    Yamamoto, T.
    Sawada, M.
    Kuroboshi, H.
    Tatsumi, H.
    Iwasaku, K.
    Kitawaki, J.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2014, 35 (01) : 11 - 15
  • [46] Prospective study of fertility-sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women
    Ouasti, Samia
    Bucau, Margot
    Larouzee, Elise
    Clement De Givry, Sebastien
    Chabbert-Buffet, Nathalie
    Koskas, Martin
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2022, 157 (02) : 452 - 457
  • [47] Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
    Yingqiao Ding
    Yuan Fan
    Xingchen Li
    Yiqin Wang
    Jianliu Wang
    Li Tian
    Reproductive Biology and Endocrinology, 20
  • [48] Cancer Incidence in Patients with Atypical Endometrial Hyperplasia Managed by Primary Hysterectomy or Fertility-sparing Treatment
    Gonthier, Clementine
    Piel, Bruno
    Touboul, Cyril
    Walker, Francine
    Cortez, Annie
    Luton, Dominique
    Darai, Emile
    Koskas, Martin
    ANTICANCER RESEARCH, 2015, 35 (12) : 6799 - 6804
  • [49] Retreatment with progestin for recurrence after complete response with fertility-sparing treatment in patients with endometrial cancer
    Lee, A. Jin
    Shim, Seung-Hyuk
    Kim, Nae Ry
    Yang, Eun Jung
    So, Kyeong A.
    Lee, Sun Joo
    Lee, Ji Young
    Kim, Tae Jin
    Kang, Soon-Beom
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (08) : 1001 - 1008
  • [50] INSULIN RESISTANCE AFFECTS THE THERAPEUTIC EFFECT OF FERTILITY-SPARING TREATMENT IN PATIENTS WITH ENDOMETRIAL ATYPICAL HYPERPLASIA
    Yang, B.
    Chen, X.
    Luo, X.
    Cheng, Y.
    Shan, W.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1286 - 1286